# InSightec

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/insightec

- Industry: Medical Devices & Equipment
- Headquarters: Tirat Carmel, Israel
- Website: www.insightec.com
- Total disclosed funding: $500M
- Latest round: Series D (Jun 18, 2024)
- Investors on record: 15

## About

Based in Israel, InSightec, Ltd. operates as a pioneer in medical technology, specializing in focused ultrasound solutions for non-invasive surgical treatments targeting neurological conditions.InSightec, Ltd. is a medical technology company that specializes in incisionless surgery. Founded in 1999 in Tirat Carmel, Israel, the company has successfully executed 18 deals. Achal Singh is the founder of InSightec, while Maurice Ferre serves as the CEO. The company recently raised USD 150.00 mn in funding from investors including Ally Bridge Group, Baillie Gifford, and others, bringing the total amount raised to USD 150.00 mn.InSightec specializes in innovative medical technology, primarily focusing on incisionless surgery through its flagship product, Exablate Neuro. This system utilizes focused ultrasound technology to precisely target and ablate tissue in the brain, specifically addressing conditions such as Essential Tremor and Tremor-Dominant Parkinson’s Disease. The treatment process is guided by MRI, allowing for real-time monitoring and patient-specific planning, enhancing safety and efficacy. The Exablate Neuro system is designed for outpatient use, enabling patients to often return home the same day after treatment. InSightec's solutions cater to healthcare professionals, including neurosurgeons and hospitals, primarily focusing on markets in North America, Europe, and Asia, where there is a significant demand for advanced therapeutic options in neurology.InSightec generates revenue primarily through the sale and service of its Exablate Neuro systems, along with associated consumables and software. The company engages in B2B transactions, working directly with healthcare facilities and surgical centers. Typical transactions involve the leasing or purchase of the Exablate Neuro system, complemented by ongoing training and support services for medical staff. InSightec may also offer subscription-based access to software updates and system enhancements, ensuring that clients have the latest technological capabilities. This structured approach facilitates long-term partnerships with healthcare providers, fostering a consistent revenue stream through both initial system sales and subsequent service agreements.InSightec, Ltd. intends to utilize its recent funding to support the development of new products and expand into additional markets. The company plans to enhance the Exablate Neuro system's capabilities and introduce new applications for focused ultrasound technology. Additionally, InSightec is targeting expansion into new geographic regions, with a focus on increasing its presence in Asia and Europe by 2025. Recent funding will also support the entry into these new markets as well as the ongoing development of new product offerings.

## Funding rounds

- Series D, Jun 18, 2024, $150M — York Capital Management, Fidelity Investments, Ally Bridge Group, Perceptive Advisors, Baillie Gifford, Fayez Sarofim & Co., Catalio Capital Management, Gilmartin Capital, Nexus NeuroTech Ventures
- Series F, Mar 6, 2020, $150M — Koch Disruptive Technologies
- Series E, Dec 14, 2017, $150M — MediTech Partners, York Capital Management, GE Healthcare, Elbit Medical Imaging, Go Capital, Focus Holdings LLC, Koch Disruptive Technologies
- Series D, Jun 30, 2014, $50M — York Capital Management

## Investors

- York Capital Management (https://capitalatlas.ai/funds/york-capital-management) — Series D, Series E
- MediTech Partners (https://capitalatlas.ai/funds/meditech-partners) — Series E
- GE Healthcare — Series E
- Elbit Medical Imaging — Series E
- Go Capital — Series E
- Focus Holdings LLC — Series E
- Koch Disruptive Technologies (https://capitalatlas.ai/funds/koch-disruptive-technologies) — Series E, Series F
- Fidelity Investments (https://capitalatlas.ai/funds/fidelity-investments) — Series D
- Ally Bridge Group (https://capitalatlas.ai/funds/ally-bridge-group) — Series D
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series D
- Baillie Gifford (https://capitalatlas.ai/funds/baillie-gifford) — Series D
- Fayez Sarofim & Co. — Series D
- Catalio Capital Management (https://capitalatlas.ai/funds/catalio-capital-management) — Series D
- Gilmartin Capital (https://capitalatlas.ai/funds/gilmartin-capital) — Series D
- Nexus NeuroTech Ventures (https://capitalatlas.ai/funds/nexus-neurotech-ventures) — Series D